Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-12-05

AUTHORS

Julien Edeline, Laurence Crouzet, Samuel Le Sourd, Claire Larible, Angélique Brunot, Florence Le Roy, Catherine Cattenoz, Marianne Latournerie, Daniel Gédouin, Anne Guillygomarc’h, Eveline Boucher

ABSTRACT

PurposeSorafenib is the standard of care for advanced hepatocellular carcinoma (HCC). The peak incidence of HCC is around 70 years. We aimed to evaluate safety and efficacy of sorafenib in the elderly population.MethodsWe retrospectively reviewed data from patients treated with sorafenib for HCC at our institution. We compared safety and efficacy data across different age groups.ResultsSince 2005, 129 patients were treated, 78 (60.5 %) were <70 years old and 51 (39.5 %) were ≥70. The frequency of dose reduction was similar between the two groups (48.7 vs. 58.8 %), as was the occurrence of severe toxicities (41.0 vs. 51.0 %) and hospitalization due to toxicity (9.0 vs. 13.7 %). However, asthenia and bleeding were more frequent in the elderly. The higher frequency of bleeding was explained by concomitant antiplatelet treatments, and major asthenia was frequent in PS1 elderly patients. There was a trend toward less frequent interruption of treatment in the younger group (25.6 vs. 39.2 %) and significantly less frequent definitive discontinuation of treatment due to toxicity (24.4 vs. 45.1 %). Median progression-free survival was 5.6 months in both age groups, while median overall survival was 9.6 months in the younger age group and 12.6 months in the older age group.ConclusionSorafenib showed similar results in terms of safety and efficacy in the elderly and younger HCC populations. Careful baseline evaluation is needed for patient’s selection in the elderly population, including discussion about antiplatelet therapy discontinuation and caution in PS1 patients, as well as active management of toxicity. More... »

PAGES

215-219

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-014-2645-z

DOI

http://dx.doi.org/10.1007/s00280-014-2645-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1033826451

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25477009


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Asthenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Hepatocellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Comorbidity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Monitoring", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "France", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemorrhage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Portal Vein", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sorafenib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Burden", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Venous Thrombosis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Edeline", 
        "givenName": "Julien", 
        "id": "sg:person.0657306623.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657306623.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Crouzet", 
        "givenName": "Laurence", 
        "id": "sg:person.0611173423.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611173423.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Sourd", 
        "givenName": "Samuel", 
        "id": "sg:person.01110132160.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110132160.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larible", 
        "givenName": "Claire", 
        "id": "sg:person.01156245360.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156245360.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brunot", 
        "givenName": "Ang\u00e9lique", 
        "id": "sg:person.01224360560.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224360560.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hepatology Department, CHU Pontchaillou, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.414271.5", 
          "name": [
            "Hepatology Department, CHU Pontchaillou, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Roy", 
        "givenName": "Florence", 
        "id": "sg:person.01272473760.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272473760.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 de coordination en oncog\u00e9riatrie Bretagne, Rennes, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Geriatry Department, CHU La Tauvrais, Rennes, France", 
            "Unit\u00e9 de coordination en oncog\u00e9riatrie Bretagne, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cattenoz", 
        "givenName": "Catherine", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hepatology Department, CHU Pontchaillou, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.414271.5", 
          "name": [
            "Hepatology Department, CHU Pontchaillou, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Latournerie", 
        "givenName": "Marianne", 
        "id": "sg:person.01013550742.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013550742.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Unit\u00e9 de coordination en oncog\u00e9riatrie Bretagne, Rennes, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France", 
            "Unit\u00e9 de coordination en oncog\u00e9riatrie Bretagne, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "G\u00e9douin", 
        "givenName": "Daniel", 
        "id": "sg:person.0716046557.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716046557.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hepatology Department, CHU Pontchaillou, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.414271.5", 
          "name": [
            "Hepatology Department, CHU Pontchaillou, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guillygomarc\u2019h", 
        "givenName": "Anne", 
        "id": "sg:person.01074300205.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074300205.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France", 
          "id": "http://www.grid.ac/institutes/grid.417988.b", 
          "name": [
            "Medical Oncology Department, Centre Eug\u00e8ne Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boucher", 
        "givenName": "Eveline", 
        "id": "sg:person.0665747347.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665747347.57"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12032-012-0446-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045196944", 
          "https://doi.org/10.1007/s12032-012-0446-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-011-1616-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026556889", 
          "https://doi.org/10.1007/s00280-011-1616-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40266-013-0124-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046922331", 
          "https://doi.org/10.1007/s40266-013-0124-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12-05", 
    "datePublishedReg": "2014-12-05", 
    "description": "PurposeSorafenib is the standard of care for advanced hepatocellular carcinoma (HCC). The peak incidence of HCC is around 70\u00a0years. We aimed to evaluate safety and efficacy of sorafenib in the elderly population.MethodsWe retrospectively reviewed data from patients treated with sorafenib for HCC at our institution. We compared safety and efficacy data across different age groups.ResultsSince 2005, 129 patients were treated, 78 (60.5\u00a0%) were <70\u00a0years old and 51 (39.5\u00a0%) were \u226570. The frequency of dose reduction was similar between the two groups (48.7 vs. 58.8\u00a0%), as was the occurrence of severe toxicities (41.0 vs. 51.0\u00a0%) and hospitalization due to toxicity (9.0 vs. 13.7\u00a0%). However, asthenia and bleeding were more frequent in the elderly. The higher frequency of bleeding was explained by concomitant antiplatelet treatments, and major asthenia was frequent in PS1 elderly patients. There was a trend toward less frequent interruption of treatment in the younger group (25.6 vs. 39.2\u00a0%) and significantly less frequent definitive discontinuation of treatment due to toxicity (24.4 vs. 45.1\u00a0%). Median progression-free survival was 5.6\u00a0months in both age groups, while median overall survival was 9.6\u00a0months in the younger age group and 12.6\u00a0months in the older age group.ConclusionSorafenib showed similar results in terms of safety and efficacy in the elderly and younger HCC populations. Careful baseline evaluation is needed for patient\u2019s selection in the elderly population, including discussion about antiplatelet therapy discontinuation and caution in PS1 patients, as well as active management of toxicity.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-014-2645-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "75"
      }
    ], 
    "keywords": [
      "hepatocellular carcinoma", 
      "age groups", 
      "elderly patients", 
      "elderly population", 
      "median progression-free survival", 
      "concomitant antiplatelet treatment", 
      "careful baseline evaluation", 
      "antiplatelet therapy discontinuation", 
      "progression-free survival", 
      "median overall survival", 
      "advanced hepatocellular carcinoma", 
      "efficacy of sorafenib", 
      "standard of care", 
      "younger age groups", 
      "older age groups", 
      "different age groups", 
      "major asthenia", 
      "definitive discontinuation", 
      "sorafenib use", 
      "antiplatelet treatment", 
      "therapy discontinuation", 
      "overall survival", 
      "HCC population", 
      "platelet aggregation inhibitors", 
      "patient selection", 
      "peak incidence", 
      "efficacy data", 
      "ResultsSince 2005", 
      "severe toxicity", 
      "baseline evaluation", 
      "dose reduction", 
      "patients", 
      "PS1 patients", 
      "younger group", 
      "terms of safety", 
      "discontinuation", 
      "months", 
      "asthenia", 
      "bleeding", 
      "carcinoma", 
      "sorafenib", 
      "treatment", 
      "aggregation inhibitors", 
      "toxicity", 
      "efficacy", 
      "survival", 
      "group", 
      "safety", 
      "population", 
      "frequent interruptions", 
      "ConclusionSorafenib", 
      "similar results", 
      "hospitalization", 
      "PurposeSorafenib", 
      "high frequency", 
      "caution", 
      "active management", 
      "years", 
      "MethodsWe", 
      "incidence", 
      "care", 
      "inhibitors", 
      "use", 
      "interruption", 
      "frequency", 
      "management", 
      "data", 
      "evaluation", 
      "occurrence", 
      "reduction", 
      "institutions", 
      "standards", 
      "selection", 
      "trends", 
      "results", 
      "discussion", 
      "terms"
    ], 
    "name": "Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors", 
    "pagination": "215-219", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1033826451"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-014-2645-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25477009"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-014-2645-z", 
      "https://app.dimensions.ai/details/publication/pub.1033826451"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_622.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-014-2645-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2645-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2645-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2645-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-014-2645-z'


 

This table displays all metadata directly associated to this object as RDF triples.

336 TRIPLES      22 PREDICATES      133 URIs      122 LITERALS      34 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-014-2645-z schema:about N0eccfe5b8cb94f5782a9251c1be8e0d8
2 N160fc3ae4ba3412aa0bba9174d77ae49
3 N19a2ea86f0df484d96ae2f24c32560f2
4 N1d9054a8deb84cf396b53931ee199d07
5 N29aa8cf5a27645318d3e4c782512f439
6 N2d67b8e24e54426eb0430ffa5d493f3b
7 N4122d5b25e284ceeb7522680628959e5
8 N47e31d48472a4c2299e4b297518afd5d
9 N47e794c91c3d46d6a793d014ab65202f
10 N5d353ae9d21b4ecdbb9d862c41694616
11 N5f64fbfda5024356976811eeb7a82215
12 N649093c0aee54fd1a95a81934cb21cd9
13 N64a4916e928147098fdf00740e1325df
14 N69057c72a2f342a488bc1f52e2188623
15 N6a04911e0acd480897d00bb11d1dee2b
16 N6a85622656964f6695e4002d4fbee5b9
17 Na08fcaecaad6444985073f7d0d41805c
18 Naa53a57ba2624f3badb87f56fa334160
19 Nba70daad367b49d3bb7c198c4e1b59df
20 Nc26600f802254893975a289c2e766e45
21 Nc2a4e1f2fc2541c4861b7409ef75a07a
22 Nc49cef843171416da4b8ed650f65b0b1
23 Nc55fc9d2687f4b71b60129c49cc6581a
24 Nca8017ac2e2d487397b942fd21891273
25 Nd0cbc5350909405ba4709861e3d714b5
26 Nd71351781d3b443ca9621bbb160083b3
27 Ndd72c9245c7b42c49eba9f241ff3a3a8
28 anzsrc-for:11
29 anzsrc-for:1103
30 schema:author Ndeddc7953d16434ebf5279407b507b7c
31 schema:citation sg:pub.10.1007/s00280-011-1616-x
32 sg:pub.10.1007/s12032-012-0446-y
33 sg:pub.10.1007/s40266-013-0124-6
34 schema:datePublished 2014-12-05
35 schema:datePublishedReg 2014-12-05
36 schema:description PurposeSorafenib is the standard of care for advanced hepatocellular carcinoma (HCC). The peak incidence of HCC is around 70 years. We aimed to evaluate safety and efficacy of sorafenib in the elderly population.MethodsWe retrospectively reviewed data from patients treated with sorafenib for HCC at our institution. We compared safety and efficacy data across different age groups.ResultsSince 2005, 129 patients were treated, 78 (60.5 %) were <70 years old and 51 (39.5 %) were ≥70. The frequency of dose reduction was similar between the two groups (48.7 vs. 58.8 %), as was the occurrence of severe toxicities (41.0 vs. 51.0 %) and hospitalization due to toxicity (9.0 vs. 13.7 %). However, asthenia and bleeding were more frequent in the elderly. The higher frequency of bleeding was explained by concomitant antiplatelet treatments, and major asthenia was frequent in PS1 elderly patients. There was a trend toward less frequent interruption of treatment in the younger group (25.6 vs. 39.2 %) and significantly less frequent definitive discontinuation of treatment due to toxicity (24.4 vs. 45.1 %). Median progression-free survival was 5.6 months in both age groups, while median overall survival was 9.6 months in the younger age group and 12.6 months in the older age group.ConclusionSorafenib showed similar results in terms of safety and efficacy in the elderly and younger HCC populations. Careful baseline evaluation is needed for patient’s selection in the elderly population, including discussion about antiplatelet therapy discontinuation and caution in PS1 patients, as well as active management of toxicity.
37 schema:genre article
38 schema:inLanguage en
39 schema:isAccessibleForFree false
40 schema:isPartOf N398187b707a447559f61a9ef7a59cc4a
41 Na26d381a32cc4002b0febd85c9e719c0
42 sg:journal.1088364
43 schema:keywords ConclusionSorafenib
44 HCC population
45 MethodsWe
46 PS1 patients
47 PurposeSorafenib
48 ResultsSince 2005
49 active management
50 advanced hepatocellular carcinoma
51 age groups
52 aggregation inhibitors
53 antiplatelet therapy discontinuation
54 antiplatelet treatment
55 asthenia
56 baseline evaluation
57 bleeding
58 carcinoma
59 care
60 careful baseline evaluation
61 caution
62 concomitant antiplatelet treatment
63 data
64 definitive discontinuation
65 different age groups
66 discontinuation
67 discussion
68 dose reduction
69 efficacy
70 efficacy data
71 efficacy of sorafenib
72 elderly patients
73 elderly population
74 evaluation
75 frequency
76 frequent interruptions
77 group
78 hepatocellular carcinoma
79 high frequency
80 hospitalization
81 incidence
82 inhibitors
83 institutions
84 interruption
85 major asthenia
86 management
87 median overall survival
88 median progression-free survival
89 months
90 occurrence
91 older age groups
92 overall survival
93 patient selection
94 patients
95 peak incidence
96 platelet aggregation inhibitors
97 population
98 progression-free survival
99 reduction
100 results
101 safety
102 selection
103 severe toxicity
104 similar results
105 sorafenib
106 sorafenib use
107 standard of care
108 standards
109 survival
110 terms
111 terms of safety
112 therapy discontinuation
113 toxicity
114 treatment
115 trends
116 use
117 years
118 younger age groups
119 younger group
120 schema:name Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors
121 schema:pagination 215-219
122 schema:productId N071be31ff77e485499fef97849228343
123 N6c93106a6435486b8d7e495912ad47e3
124 Nce22d32c6e0844c799d48dc8bd995504
125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033826451
126 https://doi.org/10.1007/s00280-014-2645-z
127 schema:sdDatePublished 2022-05-20T07:29
128 schema:sdLicense https://scigraph.springernature.com/explorer/license/
129 schema:sdPublisher Ne96041af99d64fe98500a7ae740690c9
130 schema:url https://doi.org/10.1007/s00280-014-2645-z
131 sgo:license sg:explorer/license/
132 sgo:sdDataset articles
133 rdf:type schema:ScholarlyArticle
134 N071be31ff77e485499fef97849228343 schema:name pubmed_id
135 schema:value 25477009
136 rdf:type schema:PropertyValue
137 N0eccfe5b8cb94f5782a9251c1be8e0d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Niacinamide
139 rdf:type schema:DefinedTerm
140 N160fc3ae4ba3412aa0bba9174d77ae49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Aged
142 rdf:type schema:DefinedTerm
143 N173fe895fc624f8d929eb5acb02ffdbe rdf:first sg:person.01110132160.38
144 rdf:rest Nb928a2ae2c2e49ccabccd86760fc62e7
145 N19a2ea86f0df484d96ae2f24c32560f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Retrospective Studies
147 rdf:type schema:DefinedTerm
148 N1d9054a8deb84cf396b53931ee199d07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Drug Monitoring
150 rdf:type schema:DefinedTerm
151 N29aa8cf5a27645318d3e4c782512f439 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Aged, 80 and over
153 rdf:type schema:DefinedTerm
154 N2d67b8e24e54426eb0430ffa5d493f3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Comorbidity
156 rdf:type schema:DefinedTerm
157 N398187b707a447559f61a9ef7a59cc4a schema:issueNumber 1
158 rdf:type schema:PublicationIssue
159 N4122d5b25e284ceeb7522680628959e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Venous Thrombosis
161 rdf:type schema:DefinedTerm
162 N47e31d48472a4c2299e4b297518afd5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Carcinoma, Hepatocellular
164 rdf:type schema:DefinedTerm
165 N47e794c91c3d46d6a793d014ab65202f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Incidence
167 rdf:type schema:DefinedTerm
168 N54a56d6f10e14df381e54befb9e09952 rdf:first sg:person.01074300205.48
169 rdf:rest N5e832ffd48a94da79f33a627c986e895
170 N5d353ae9d21b4ecdbb9d862c41694616 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Male
172 rdf:type schema:DefinedTerm
173 N5e832ffd48a94da79f33a627c986e895 rdf:first sg:person.0665747347.57
174 rdf:rest rdf:nil
175 N5f64fbfda5024356976811eeb7a82215 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Liver Neoplasms
177 rdf:type schema:DefinedTerm
178 N649093c0aee54fd1a95a81934cb21cd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Hemorrhage
180 rdf:type schema:DefinedTerm
181 N64a4916e928147098fdf00740e1325df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Female
183 rdf:type schema:DefinedTerm
184 N69057c72a2f342a488bc1f52e2188623 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Survival Analysis
186 rdf:type schema:DefinedTerm
187 N6a04911e0acd480897d00bb11d1dee2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Phenylurea Compounds
189 rdf:type schema:DefinedTerm
190 N6a85622656964f6695e4002d4fbee5b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Antineoplastic Agents
192 rdf:type schema:DefinedTerm
193 N6c93106a6435486b8d7e495912ad47e3 schema:name dimensions_id
194 schema:value pub.1033826451
195 rdf:type schema:PropertyValue
196 N87ab1b9e207c4c5683abba40c5a7c177 rdf:first sg:person.0611173423.13
197 rdf:rest N173fe895fc624f8d929eb5acb02ffdbe
198 Na08fcaecaad6444985073f7d0d41805c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Platelet Aggregation Inhibitors
200 rdf:type schema:DefinedTerm
201 Na26d381a32cc4002b0febd85c9e719c0 schema:volumeNumber 75
202 rdf:type schema:PublicationVolume
203 Naa53a57ba2624f3badb87f56fa334160 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Tumor Burden
205 rdf:type schema:DefinedTerm
206 Nacdd1a010d6f4d03a0a86d9cf8b09ecf schema:affiliation grid-institutes:None
207 schema:familyName Cattenoz
208 schema:givenName Catherine
209 rdf:type schema:Person
210 Nb45622851fc945a195847f732d6c7717 rdf:first Nacdd1a010d6f4d03a0a86d9cf8b09ecf
211 rdf:rest Nbe6e2166b21a48558631096be3097c05
212 Nb928a2ae2c2e49ccabccd86760fc62e7 rdf:first sg:person.01156245360.54
213 rdf:rest Nd06dc117e74e44a48522511254f73b86
214 Nba70daad367b49d3bb7c198c4e1b59df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Sorafenib
216 rdf:type schema:DefinedTerm
217 Nbe6e2166b21a48558631096be3097c05 rdf:first sg:person.01013550742.30
218 rdf:rest Nee1fe64136d74de99e8a04dde9940f39
219 Nc26600f802254893975a289c2e766e45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name France
221 rdf:type schema:DefinedTerm
222 Nc2a4e1f2fc2541c4861b7409ef75a07a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Liver
224 rdf:type schema:DefinedTerm
225 Nc3d1ce31d9a54ec3be01d41c2c098dd0 rdf:first sg:person.01272473760.08
226 rdf:rest Nb45622851fc945a195847f732d6c7717
227 Nc49cef843171416da4b8ed650f65b0b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Asthenia
229 rdf:type schema:DefinedTerm
230 Nc55fc9d2687f4b71b60129c49cc6581a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
231 schema:name Aging
232 rdf:type schema:DefinedTerm
233 Nca8017ac2e2d487397b942fd21891273 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
234 schema:name Drug Interactions
235 rdf:type schema:DefinedTerm
236 Nce22d32c6e0844c799d48dc8bd995504 schema:name doi
237 schema:value 10.1007/s00280-014-2645-z
238 rdf:type schema:PropertyValue
239 Nd06dc117e74e44a48522511254f73b86 rdf:first sg:person.01224360560.83
240 rdf:rest Nc3d1ce31d9a54ec3be01d41c2c098dd0
241 Nd0cbc5350909405ba4709861e3d714b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
242 schema:name Portal Vein
243 rdf:type schema:DefinedTerm
244 Nd71351781d3b443ca9621bbb160083b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
245 schema:name Follow-Up Studies
246 rdf:type schema:DefinedTerm
247 Ndd72c9245c7b42c49eba9f241ff3a3a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
248 schema:name Humans
249 rdf:type schema:DefinedTerm
250 Ndeddc7953d16434ebf5279407b507b7c rdf:first sg:person.0657306623.46
251 rdf:rest N87ab1b9e207c4c5683abba40c5a7c177
252 Ne96041af99d64fe98500a7ae740690c9 schema:name Springer Nature - SN SciGraph project
253 rdf:type schema:Organization
254 Nee1fe64136d74de99e8a04dde9940f39 rdf:first sg:person.0716046557.51
255 rdf:rest N54a56d6f10e14df381e54befb9e09952
256 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
257 schema:name Medical and Health Sciences
258 rdf:type schema:DefinedTerm
259 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
260 schema:name Clinical Sciences
261 rdf:type schema:DefinedTerm
262 sg:journal.1088364 schema:issn 0344-5704
263 1432-0843
264 schema:name Cancer Chemotherapy and Pharmacology
265 schema:publisher Springer Nature
266 rdf:type schema:Periodical
267 sg:person.01013550742.30 schema:affiliation grid-institutes:grid.414271.5
268 schema:familyName Latournerie
269 schema:givenName Marianne
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013550742.30
271 rdf:type schema:Person
272 sg:person.01074300205.48 schema:affiliation grid-institutes:grid.414271.5
273 schema:familyName Guillygomarc’h
274 schema:givenName Anne
275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074300205.48
276 rdf:type schema:Person
277 sg:person.01110132160.38 schema:affiliation grid-institutes:grid.417988.b
278 schema:familyName Le Sourd
279 schema:givenName Samuel
280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110132160.38
281 rdf:type schema:Person
282 sg:person.01156245360.54 schema:affiliation grid-institutes:grid.417988.b
283 schema:familyName Larible
284 schema:givenName Claire
285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156245360.54
286 rdf:type schema:Person
287 sg:person.01224360560.83 schema:affiliation grid-institutes:grid.417988.b
288 schema:familyName Brunot
289 schema:givenName Angélique
290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224360560.83
291 rdf:type schema:Person
292 sg:person.01272473760.08 schema:affiliation grid-institutes:grid.414271.5
293 schema:familyName Le Roy
294 schema:givenName Florence
295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272473760.08
296 rdf:type schema:Person
297 sg:person.0611173423.13 schema:affiliation grid-institutes:grid.417988.b
298 schema:familyName Crouzet
299 schema:givenName Laurence
300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611173423.13
301 rdf:type schema:Person
302 sg:person.0657306623.46 schema:affiliation grid-institutes:grid.417988.b
303 schema:familyName Edeline
304 schema:givenName Julien
305 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657306623.46
306 rdf:type schema:Person
307 sg:person.0665747347.57 schema:affiliation grid-institutes:grid.417988.b
308 schema:familyName Boucher
309 schema:givenName Eveline
310 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665747347.57
311 rdf:type schema:Person
312 sg:person.0716046557.51 schema:affiliation grid-institutes:None
313 schema:familyName Gédouin
314 schema:givenName Daniel
315 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716046557.51
316 rdf:type schema:Person
317 sg:pub.10.1007/s00280-011-1616-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1026556889
318 https://doi.org/10.1007/s00280-011-1616-x
319 rdf:type schema:CreativeWork
320 sg:pub.10.1007/s12032-012-0446-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1045196944
321 https://doi.org/10.1007/s12032-012-0446-y
322 rdf:type schema:CreativeWork
323 sg:pub.10.1007/s40266-013-0124-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046922331
324 https://doi.org/10.1007/s40266-013-0124-6
325 rdf:type schema:CreativeWork
326 grid-institutes:None schema:alternateName Unité de coordination en oncogériatrie Bretagne, Rennes, France
327 schema:name Geriatry Department, CHU La Tauvrais, Rennes, France
328 Medical Oncology Department, Centre Eugène Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France
329 Unité de coordination en oncogériatrie Bretagne, Rennes, France
330 rdf:type schema:Organization
331 grid-institutes:grid.414271.5 schema:alternateName Hepatology Department, CHU Pontchaillou, Rennes, France
332 schema:name Hepatology Department, CHU Pontchaillou, Rennes, France
333 rdf:type schema:Organization
334 grid-institutes:grid.417988.b schema:alternateName Medical Oncology Department, Centre Eugène Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France
335 schema:name Medical Oncology Department, Centre Eugène Marquis, Av de la bataille Flandres Dunkerque, 35043, Rennes, France
336 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...